sababbin cutar sankarar mahaifa 2020

A shekarar 2020, an sanya ci gaba mai mahimmanci a cikin cutar sankarau, gami da amincewa da sabbin magungunan da aka yi niyya, suna bayar da ingantattun sakamako kuma ke da kai ga marasa lafiya. Wadannan fashewar sun samar da sabbin zaɓuɓɓuka na wungling, suna magance takamaiman maye gurbi da kuma inganta amsawar jikin mutum ta jiki don yakar da cutar ta jiki don yakar kararraki: Key Sababbin cutar sankarar mahaifa 20202020 yayi alama mai mahimmanci a cikin yaki da cutar sankara. Yayin da shekara ta Pandemication ta mamaye ta duniya ta mamaye shekarar duniya ta mamaye shekarar duniya ta ci gaba da tura iyakokin zaɓin magani. Da yawa suna ba da gudummawa da suka faru, suna ba da fatan da marasa lafiya da sake sauya yanayin yanayin cutar ta huhu. Cibiyar Bincike ta Cibiyar Shaidar Cibiyar Cutar Cutar Cutar Cutar Cutar Cutar Cutar Shander ta biyo bayan wadannan cigaba (Egfr) Mutsi na yau da kullun ne a cikin ƙananan ƙwayar sel mara ƙarfi (NSCLC). A shekarar 2020, sabo da inganta abubuwan da ake ba da izini, suna ba da ingantacciyar rayuwa mai zurfi ga marasa lafiya tare da waɗannan maye gurbi. Wadannan masu hana su ne ke hana su sau da yawa suna shawo kan juriya da ke iyakance tasirin magungunan da suka gabata. Musamman, wakilai masu niyya daga manyan maye gurbi na Egfr sun nuna wajan alkawuran da suka yi. Tebur mai zuwa yana nuna sakamakon gwaji na asibiti na Amvantamab: Tsarin gwajin gabaɗaya gabaɗaya (ORR) Lokaci guda 40% na yau da kullun: FDAAlk inhibitors: faɗakarwar abubuwan da aka jurewa Yawancin masu hana daukaroran Alk sun riga sun kasance suna nan, kuma a cikin 2020, bincike da ya mai da hankali kan juriya ga wadannan kwayoyi da bunkasa karfi daular. New combination therapies were also explored to improve outcomes in ALK-positive lung cancer.Immunotherapy: Harnessing the Power of the Immune SystemImmunotherapy, which boosts the body's immune system to fight cancer, continued to be a major area of ​​progress in lung cancer treatment in 2020.Checkpoint Inhibitors in Earlier StagesCheckpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized lura da cutar sankarar mahaifa. A cikin 2020, bincike sun bincika amfanin waɗannan magunguna a cikin matakan cutar, ciki har da bayan tiyata ko a hade tare da chemotherapy. Wadannan nazarin da aka nuna cewa rigakafi na iya inganta matakan rayuwa kuma ku rage haɗarin sake sarrafa cuta kuma ya bincika magunguna daban-daban don haɓaka tasiri daban-daban na ƙwaƙwalwar ajiya. Tushewar Binciken Dual, ta amfani da nau'ikan wuraren shakatawa na rigakafi na rigakafi na rigakafi, sun nuna alƙawarin a wasu marasa lafiya waɗanda ba su amsa wa memermanmunothera ba. Ana ci gaba da gwaji na asibiti don tabbatar da waɗannan haɗi na gabatowa don gano mahimmancin da ke tattare da ci gaban bidiniyya a cikin ciwon daji na halittar. A shekarar 2020, an sami fifiko game da gwaji don mahimman maye gurbi da PD-L1 furucin ra'ayi don yanke shawara na jagoranci. Wannan hanyar sirri tana tabbatar da cewa marasa lafiyar cututtukan cututtukan cututtukan daji na asali. Cibiyar Binciken Cancanci don cimma mafi kyawun gwaji don cimma mafi kyawun sakamako. Sabuwar Kansu na Yan Irga Lung Hanyar har ma da ƙarin ci gaba a cikin shekaru masu zuwa. Bincike mai gudana yana mai da hankali kan tasirin sabbin magungunan da aka yi niyya, inganta hanyoyin rigakafi, da kuma gano masu biomaraki. Babban burin shine don samar da ingantaccen tasiri da keɓaɓɓen yanayin rayuwa da ingancin rayuwa ga duk marasa lafiyar mahaifa a cikin cutar sankarar mahaifa. Yarjejeniyar sababbin kwayar halittar da ta rigakafi, tare da karuwar girmamawa kan gwajin biomarrer, sun canza yanayin yanayin cutar ta huhu. Wadannan abubuwan da suka faru na bayar da fatan masu haƙuri da danginsu kuma suka nuna mahimmancin ci gaba da bincike da ci gaba da yaƙi da wannan cuta mai lalata. Yi la'akari da ziyarar Shandong Baofa Ceter Center Cibiyar Shafin yanar gizo don ƙarin bayani game da gwaji na asibiti da jiyya na cutar kansa.